<DOC>
	<DOCNO>NCT00983580</DOCNO>
	<brief_summary>This phase II trial study well give acetylsalicylic acid together eflornithine work treat patient high risk colorectal cancer . Chemoprevention use certain drug keep cancer forming . The use acetylsalicylic acid eflornithine may prevent colorectal cancer .</brief_summary>
	<brief_title>Acetylsalicylic Acid Eflornithine Treating Patients High Risk Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The proportion subject adenoma recurrence 1-year follow-up colonoscopy exam . This adenoma recurrence rate difluoromethylornithine ( DFMO ) ( eflornithine ) + aspirin compare double placebo see improvement adenoma recurrence rate patient population . SECONDARY OBJECTIVES : I . To determine relative tolerability safety treatment regimen administer 12 month . II . To determine effect study drug ( aspirin [ acetylsalicylic acid ] + DFMO ) placebo respect proliferation ( Ki67 label index ) , apoptosis ( caspase-3 expression assay ) , drug effect marker ( COX-1 , -2 , polyamines , PGE2 ) adenoma , aberrant crypt focus ( ACF ) normal-appearing mucosa use pre- 12-month post-intervention tissue biopsy sample . III . To estimate percentage change rectal ACF number , determine magnify colonoscopy subject treat 12 month placebo study drug ( aspirin +DFMO ) compare % change drug versus placebo arm . IV . To characterize ACF base three criterion ( ACF size [ crypt number &lt; 50 &gt; = 50 ] , crypt morphology characteristic , histology ) ACF correlate characteristic intervention ( vs placebo ) . Also , evaluate natural history ACF 1-year placebo . V. To correlate 12-month measurement ACF size ( # crypts/ACF ) , number , morphology , histopathology adenoma recurrence data 12 36 month ; correlate 12-month % ( actual ) change ACF size number 12- 36-month adenoma recurrence rate ; correlate adenoma recurrence data 1 year adenoma recurrence data 3 year . TERTIARY OBJECTIVES : I . To explore effect study agent focused panel tissue biomarkers pre- post-intervention biopsy sample recurrent adenoma , rectal ACF , adjacent normal-appearing mucosa among subject enrol phase II clinical trial . II . To determine cleave capase-3 expression improve detection apoptotic cell recognize cellular commitment apoptosis prior late nuclear morphologic feature correlate apoptotic regulatory protein , histology , treatment response . III . To determine effect aspirin biochemical target COX-1 , -2 , prostaglandin E2 , polyamine level subject receive DFMO . IV . To examine COX-2-dependent gene ( i.e. , Bcl-2 DR5 ) adenomas ACF show regulate intrinsic mitochondrial extrinsic death receptor-mediated apoptotic pathway vitro vivo . V. To perform expression profile adenomas ACF relate date ACF histology , size/morphology , modulation chemopreventive agent , subsequent adenoma recurrence rate . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive acetylsalicylic acid orally ( PO ) daily eflornithine PO twice daily day 1-28 . ARM II : Patients receive placebo PO three time daily day 1-28 . Treatment repeat every 28 day 12 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 , 12 , 36 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyps</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Current prior advanced adenoma Advanced adenoma define subject polyp &gt; = 1 cm , tubulovillous adenoma ( 2575 percent villous feature ) , villous adenoma ( &gt; 75 percent villous ) , highgrade dysplasia Prior colon cancer ( &gt; = 3 year invasive cancer ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Ability willingness sign write informed consent document Willingness provide mandatory tissue research purpose Negative pregnancy test = &lt; 7 day prior randomization Hemoglobin ( Hgb ) within normal limit institution/lab Platelet count &gt; = 100,000/ul White blood cell count ( WBC ) &gt; = 3,000/ul Alanine aminotransferase ( ALT ) = &lt; 2 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) = &lt; 2 x institutional ULN Total bilirubin = &lt; 1.5 x institutional ULN Serum calcium = &lt; institutional ULN Serum creatinine = &lt; 1.5 x institutional ULN Colonoscopy = &lt; 45 day prior randomization removal adenomas polyp &gt; = 2 mm size Any history current prior rectal cancer Known diagnosis colon heritable cancer syndrome ( familial adenomatous polyposis [ FAP ] , hereditary nonpolyposis colorectal cancer [ HNPCC ] ) inflammatory bowel disease ( Crohn 's disease , ulcerative colitis ) Inability swallow pill Bleeding diathesis New diagnosis carcinoma History hypersensitivity COX2 inhibitor , sulfonamide , nonsteroidal antiinflammatory drug ( NSAIDs ) , salicylates , ursodeoxycholic acid History gastroduodenal ulcer document = &lt; 1 year Known inability participate schedule followup test Significant medical psychiatric problem would make subject poor protocol candidate , opinion treat physician Total colectomy Patients colostomy History pelvic rectal radiation therapy History invasive carcinoma = &lt; 5 year ( except subject Dukes A/B1 carcinoma = &lt; 5 year prior preregistration stage colon cancer &gt; = 3 year post surgical resection ) Acute liver disease , unexplained transaminase elevation , elevate serum calcium History allergic reaction attribute compound similar chemical composition study agent Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Concomitant corticosteroids anticoagulant need regular predictable intermittent basis New diagnosis invasive carcinoma Use nonstudy investigational agent ( ) = &lt; 3 month prior randomization Chemotherapy = &lt; 6 month prior randomization ( Note : topical chemotherapy assess casebycase basis ) Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Regular use NSAIDs = &lt; 6 week prior randomization , define frequency 7 consecutive day ( 1 week ) &gt; 3 week ( Exception : low dose aspirin [ 81 mg ] subject chronic user aspirin prior beginning study )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>